NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03395197,Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC,https://clinicaltrials.gov/study/NCT03395197,TALAPRO-2,ACTIVE_NOT_RECRUITING,This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.,YES,mCRPC,DRUG: Talazoparib with enzalutamide|DRUG: Placebo with enzalutamide,"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occuring Within the First 66 Days of Dosing - Part 1, An adverse event (AE) was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per Common Terminology Criteria for Adverse Events (CTCAE) version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. Serious TEAE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported., Post dose on Day 1 up to Day 66 in Part 1|Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by Preferred Term (PT) and Max CTCAE Grade Occuring Within the First 66 Days of Dosing - Part 1, An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1=mild AE; Grade 2=moderate AE; Grade 3=severe AE; Grade 4=life-threatening or disabling AE; Grade 5=death related to an AE. Medical Dictionary for Regulatory Activities (MedDRA) v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with at least 1 occurrence in participants are reported for this outcome measure. Results as of 16 Aug 2022 are reported., Post dose on Day 1 up to Day 66 in Part 1|Number of Participants With All-Causality TEAEs During the Overall Period of Part 1, An adverse event (AE) was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. Serious TEAE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported., Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)|Number of Participants With Treatment-Related TEAEs During the Overall Period of Part 1, An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. Treatment-related AE was any untoward medical occurrence attributed to study intervention in a participant who received study intervention. As per CTCAE version 4, Grade 1= mild AE; Grade 2= moderate AE; Grade 3= severe AE; Grade 4= life-threatening or disabling AE; Grade 5= death related to an AE. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were determined according to the investigator's assessment. Results as of 16 Aug 2022 are reported., Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)|Number of Participants With All-Causality Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade Occuring Anytime After Dosing - Part 1, An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are defined as newly occurring AEs or those worsening after first dose. As per CTCAE version 4, Grade 1=mild AE; Grade 2=moderate AE; Grade 3=severe AE; Grade 4=life-threatening or disabling AE; Grade 5=death related to an AE. MedDRA v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with at least 1 occurrence in participants are reported for this outcome measure. Results as of 16 Aug 2022 are reported., Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)|Number of Participants With Treatment-Related Clustered Treatment-Emergent Cytopenias by PT and Max CTCAE Grade in >=10% of Participants Occuring Anytime After Dosing - Part 1, An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are newly occurring AEs or those worsening after first dose. Treatment-related AE was any AE attributed to study intervention in a participant who received study intervention. As per CTCAE version 4, Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling; Grade 5=death related to an AE. MedDRA v25.0 coding dictionary applied. PTs for the cluster terms are: ANEMIA, including Anemia, Hematocrit decreased, Hemoglobin decreased, and Red blood cell count decreased; THROMBOCYTOPENIA, including, Thrombocytopenia and Platelet count decreased; NEUTROPENIA, including Febrile neutropenia, Neutropenia and Neutrophil count decreased; LEUKOPENIA, including Leukopenia, White blood cell count decreased. Events in any grade with incidence in \>=10% of participants are reported. Results as of 16 Aug 2022 are reported., Post dose on Day 1 up to 28 days after the last dose of study intervention, or before new systemic antineoplastic therapy, whichever occurred first (maximum of 235.14 weeks)|Blinded Independent Central Review (BICR) Assessed Radiographic Progression-Free Survival (rPFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for All-Comers - Part 2 Cohort 1, rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per RECIST 1.1, or death, whichever occurs first. Soft tissue disease status was assessed at regular intervals during the course of the study by computed tomography (CT) of chest and CT or magnetic resonance imaging (MRI) of abdomen and pelvis. Progression is defined using RECIST 1.1 as a \>=20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Results as of 16 Aug 2022 are reported for this outcome measure., From the start of treatment to the time of first documented progression, or death (maximum up to 42 months)|BICR Assessed rPFS Per RECIST 1.1 in Patients With DDR Deficiencies - Part 2, rPFS is defined as the time from the date of randomization to first objective evidence of radiographic progression as assessed in soft tissue per RECIST 1.1, or death, whichever occurs first. Soft tissue disease status was assessed at regular intervals during the course of the study by CT of chest and CT or MRI of abdomen and pelvis. Results as of 03 Oct 2022 are reported for this outcome measure., From the start of treatment to the time of first documented progression, or death (maximum up to 38 months)",,,Pfizer,Astellas Pharma Inc,MALE,"ADULT, OLDER_ADULT",PHASE3,1054,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",C3441021|2017-003295-31|TALAPRO-2,2017-12-18,2022-10-03,2025-12-31,2018-01-10,2024-01-17,2025-03-25,"Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, 99503, United States|Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers, Chandler, Arizona, 85224, United States|Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers, Gilbert, Arizona, 85297, United States|Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers, Mesa, Arizona, 85202, United States|Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers, Mesa, Arizona, 85206, United States|Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers, Scottsdale, Arizona, 85260, United States|Arizona Urology Specialists, Tucson, Arizona, 85715, United States|Arizona Urology Specialists, Tucson, Arizona, 85741, United States|Beverly Hills Cancer Center, Beverly Hills, California, 90211, United States|South County Hematology/Oncology, Chula Vista, California, 91911, United States|Sharp Rees-Stealy, Chula Vista, California, 91913, United States|Glendale Adventist Medical Center, Glendale, California, 91206, United States|Marin Cancer Care, Inc., Greenbrae, California, 94904, United States|Cancer Center Oncology Medical Group, La Mesa, California, 91942, United States|Loma Linda University Cancer Center - Records Management Only, Loma Linda, California, 92350, United States|Loma Linda University Cancer Center - Hematology/Oncology Clinic, Loma Linda, California, 92354, United States|Loma Linda University Medical Center, Loma Linda, California, 92354, United States|VA Long Beach Healthcare System, Long Beach, California, 90822, United States|UCLA Clark Urology Center, Los Angeles, California, 90095, United States|University of California, Irvine Medical Center, Orange, California, 92868, United States|Stanford Cancer Institute, Palo Alto, California, 94304, United States|Desert Hematology Oncology Medical Group, Incorporation, Rancho Mirage, California, 92270, United States|Eisenhower Medical Center, Rancho Mirage, California, 92270, United States|Medical Oncology Associates-SD, San Diego, California, 92123, United States|Sharp Memorial Hospital Investigational Pharmacy, San Diego, California, 92123, United States|Sharp Rees-Stealy, San Diego, California, 92123, United States|Stanford Health Care, Stanford, California, 94305, United States|University of Colorado Denver CTO/CTRC, Aurora, Colorado, 80045, United States|University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, 80045, United States|University of Colorado Hospital- Anschutz Inpatient Pavilion, Aurora, Colorado, 80045, United States|University of Colorado Hospital- Anschutz Outpatient Pavilion, Aurora, Colorado, 80045, United States|University of Colorado Hospital, Aurora, Colorado, 80045, United States|The Urology Center of Colorado, Denver, Colorado, 80211, United States|Florida Cancer Specialists, Altamonte Springs, Florida, 32701, United States|Florida Cancer Specialists, Brandon, Florida, 33511, United States|Florida Cancer Specialists, Clearwater, Florida, 33761, United States|Florida Cancer Specialists, Daytona Beach, Florida, 32117, United States|Florida Cancer Specialists, Fort Myers, Florida, 33905, United States|Florida Cancer Specialists, Gainesville, Florida, 32605, United States|Lakeland Regional Health Hollis Cancer Center, Lakeland, Florida, 33805, United States|Florida Cancer Specialists, Largo, Florida, 33770, United States|Florida Cancer Specialists, Lecanto, Florida, 34461, United States|Florida Cancer Specialists, New Port Richey, Florida, 34655, United States|Florida Cancer Specialists, Ocala, Florida, 34471, United States|Florida Cancer Specialists, Orange City, Florida, 32763, United States|AdventHealth Medical Group Hermatology and Oncology, Orlando, Florida, 32804, United States|Investigational Drug Services, Advent Health Orlando, Orlando, Florida, 32804, United States|Florida Cancer Specialists, Orlando, Florida, 32806, United States|Florida Cancer Specialists, Saint Petersburg, Florida, 33705, United States|Florida Cancer Specialists, Spring Hill, Florida, 34608, United States|Florida Cancer Specialists, Stuart, Florida, 34994, United States|Florida Cancer Specialists, Tampa, Florida, 33607, United States|Florida Cancer Specialists, Tavares, Florida, 32778, United States|Florida Cancer Specialists, The Villages, Florida, 32159, United States|Florida Cancer Specialists, Vero Beach, Florida, 32960, United States|Florida Cancer Specialists, Wellington, Florida, 33414, United States|Florida Cancer Specialists, West Palm Beach, Florida, 33401, United States|Florida Cancer Specialists, Winter Park, Florida, 32792, United States|Piedmont Cancer Institute, Atlanta, Georgia, 30318, United States|Piedmont Cancer Institute, Fayetteville, Georgia, 30214, United States|Piedmont Cancer Institute, Newnan, Georgia, 30265, United States|Southeastern Regional Medical Center, Newnan, Georgia, 30265, United States|Cook County Health (CCH), Chicago, Illinois, 60612, United States|John H. Stroger, Jr. Hospital of Cook County/IND Pharmacy, Chicago, Illinois, 60612, United States|AMITA Health Adventist Medical Center Hinsdale, Hinsdale, Illinois, 60521, United States|AMITA Health Cancer Institute, Hinsdale, Illinois, 60521, United States|Midwestern Regional Medical Center, Zion, Illinois, 60099, United States|Clark Memorial Hospital Radiology, Jeffersonville, Indiana, 47130, United States|First Urology, PSC, Jeffersonville, Indiana, 47130, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, 52242, United States|The University of Kansas Clinical Research Center, Fairway, Kansas, 66205, United States|The University of Kansas Cancer Center, Westwood, Kansas, 66205, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States|VA Saint Louis Healthcare System, Saint Louis, Missouri, 63106, United States|XCancer Omaha / Urology Cancer Center, PC d/b/a XCancer, Omaha, Nebraska, 68130, United States|Clara Maass Medical Center, Belleville, New Jersey, 07109, United States|New Jersey Cancer Care and Blood Disorders, Belleville, New Jersey, 07109, United States|University Radiology, Nutley, New Jersey, 07110, United States|New Jersey Urology, LLC, Voorhees, New Jersey, 08043, United States|Urology Group of New Mexico, Albuquerque, New Mexico, 87109, United States|San Juan Oncology Associates, Farmington, New Mexico, 87401, United States|Montefiore Medical Center - Montefiore Medical Park, Bronx, New York, 10461, United States|Premier Medical Group of the Hudson Valley PC, Poughkeepsie, New York, 12603, United States|Associated Medical Professionals of New York, PLLC, Syracuse, New York, 13210, United States|TriState urologic Services PSC Inc., dba The Urology Group, Cincinnati, Ohio, 45212, United States|Clinical Research Solutions, Middleburg Heights, Ohio, 44130, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, 73104, United States|Kaiser Sunnyside Medical Center, Clackamas, Oregon, 97015, United States|Kaiser Westside Medical Center, Hillsboro, Oregon, 97124, United States|Providence Cancer Institute Newberg Clinic, Newberg, Oregon, 97132, United States|Providence Newberg Medical Center, Newberg, Oregon, 97132, United States|Providence Cancer Institute Willamette Falls, Oregon City, Oregon, 97045, United States|Providence Cancer Institute Franz Clinic, Portland, Oregon, 97213, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|Providence Oncology and Hematology Care Clinic - Westside, Portland, Oregon, 97225, United States|Providence St Vincent Medical Center, Portland, Oregon, 97225, United States|Kaiser Permanente Northwest, Portland, Oregon, 97227, United States|UPMC Hillman Cancer Center - Altoona, Altoona, Pennsylvania, 16601, United States|UPMC Hillman Cancer Center - Upper St. Clair, Bethel Park, Pennsylvania, 15102, United States|UPMC Hillman Cancer Center - Arnold Palmer - Mt View, Greensburg, Pennsylvania, 15601, United States|Keystone Urology Specialists, Lancaster, Pennsylvania, 17604, United States|UPMC Hillman Cancer Center - Monroeville, Monroeville, Pennsylvania, 15146, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|UPMC Hillman Cancer Center - Passavant (HOA), Pittsburgh, Pennsylvania, 15237, United States|UPMC Hillman Cancer Center - Passavant (OHA), Pittsburgh, Pennsylvania, 15237, United States|UPMC Hillman Cancer Center - Northwest, Seneca, Pennsylvania, 16346, United States|UPMC Hillman Cancer Center - Uniontown, Uniontown, Pennsylvania, 15401, United States|UPMC Hillman Cancer Center - Washington, Washington, Pennsylvania, 15301, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, 29572, United States|Greco-Hainesworth Tennessee Oncology Centers for Research, Chattanooga, Tennessee, 37404, United States|Tennessee oncology, PLLC, Chattanooga, Tennessee, 37404, United States|Tennesse Oncology, PLLC, Cleveland, Tennessee, 37311, United States|Urology Associates P.C., Nashville, Tennessee, 37209, United States|The Vanderbilt Clinic, Nashville, Tennessee, 37232, United States|Vanderbuilt University Medical Center, Department of Urology, Nashville, Tennessee, 37232, United States|Urology Austin PLLC, Austin, Texas, 78745, United States|Rio Grande Urology, P.A., El Paso, Texas, 79912, United States|Houston Metro Urology, Houston, Texas, 77027, United States|Urology Austin, PLLC, Round Rock, Texas, 78681, United States|Baylor Scott & White Medical Center - Temple, Temple, Texas, 76508, United States|Farmington Health Center -University of Utah, Farmington, Utah, 84025, United States|Huntsman Cancer Hospital, Salt Lake City, Utah, 84112, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Redwood Health Center-University of Utah, Salt Lake City, Utah, 84119, United States|South Jordan Health Center -University of Utah, South Jordan, Utah, 84095, United States|Inova Schar Cancer Institute Infusion Pharmacy, Fairfax, Virginia, 22031, United States|Inova Schar Cancer Institute, Fairfax, Virginia, 22031, United States|Swedish Cancer Institute, Seattle, Washington, 98104, United States|Swedish Medical Center, Seattle, Washington, 98122, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, 53792, United States|University of Wisconsin Hospital & Clinics, Madison, Wisconsin, 53792, United States|Centro de Investigacion Pergamino SA - Clinica Pergamino SA, Pergamino, Buenos Aires, B2700CPM, Argentina|Instituto de Oncologia de Rosario, Rosario, Santa FE, S2000KZE, Argentina|Hospital Británico de Buenos Aires, Caba, C1280AEB, Argentina|Centro de Educacion Medica e Investigaciones Clinicas ""Norberto Quirno"" Cemic, Caba, C1431FWO, Argentina|Clinica Universitaria Reina Fabiola, Cordoba, X5004FHP, Argentina|Hospital Privado Centro Medico de Cordoba, Cordoba, X5016KEH, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, 2010, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, 2444, Australia|Icon Cancer Centre Wesley, Auchenflower, Queensland, 4066, Australia|River City Pharmacy, Auchenflower, Queensland, 4066, Australia|Princess Alexandra Hospital, Brisbane, Queensland, 4102, Australia|ICON Cancer Centre Chermside, Chermside, Queensland, 4032, Australia|ICON Cancer Centre South Brisbane, South Brisbane, Queensland, 4101, Australia|Integrated Clinical Oncology Network Pty Ltd (ICON), South Brisbane, Queensland, 4101, Australia|ICON Cancer Centre Southport, Southport, Queensland, 4215, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Peter MacCallum Cancer Centre, North Melbourne, Victoria, 3051, Australia|AZ Klina, Brasschaat, 2930, Belgium|A.Z. Sint-Lucas, Gent, 9000, Belgium|UZ Gent, Gent, 9000, Belgium|AZ Groeninge, Kortrijk, 8500, Belgium|Clinique Saint-Pierre Ottignies, Ottignies, 1340, Belgium|CHU UCL Namur site Godinne, Yvoir, 5530, Belgium|Instituto Nacional de Câncer José de Alencar Gomes da Silva - INCA, Rio de Janeiro, RJ, 20230-130, Brazil|Instituto Nacional de Câncer José de Alencar Gomes da Silva - INCA, Rio de Janeiro, RJ, 20231-050, Brazil|Hospital Universitario Pedro Ernesto-Centro de Pesquisas (CEPUSA), Rio de Janeiro, RJ, 20551-030, Brazil|Hospital CopaDor, Rio de Janeiro, RJ, 22031-011, Brazil|Hospital Gloria D'Or, Rio de Janeiro, RJ, 22211-230, Brazil|Oncologia D'Or, Rio de Janeiro, RJ, 22251-040, Brazil|Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, RJ, 22281-100, Brazil|Oncologia D'Or, Rio de Janeiro, RJ, 22291-110, Brazil|Associacao Hospital de Caridade de Ijui, Ijui, RS, 98700-000, Brazil|Sociedade Beneficencia e Caridade de Lajeado - Hospital Bruno Born, Lajeado, RS, 95900-022, Brazil|Centro de Pesquisa Clinica em Oncologia - Hospital Sao Lucas da Pontificia Universidade Catolica, Porto Alegre, RS, 90610-000, Brazil|Centro Gaucho Integrado - Hospital Mae de Deus, Porto Alegre, RS, 90850-170, Brazil|MedPlex Eixo Norte, Porto Alegre, RS, 91010-004, Brazil|Hospital Nossa Senhora da Conceicao - Grupo Hospitalar Conceicao, Porto Alegre, RS, 91350-200, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, SP, 14784-400, Brazil|Faculdade de Medicina do ABC - Centro de Estudos e Pesquisa de Hematologia e Oncologia (CEPHO), Santo Andre, SP, 09060-650, Brazil|Faculdade de Medicina do ABC - Centro de Estudos e Pesquisas de Hematologia e Oncologia (CEPHO), Santo Andre, SP, 09060-870, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, 01246-000, Brazil|Instituto do Cancer do Estado de Sao Paulo-ICESP-Nucleo de Pesquisa, Sao Paulo, SP, 01246-000, Brazil|Hospital Alemão Oswaldo Cruz, Sao Paulo, SP, 01327-001, Brazil|Tom Baker Cancer Centre - Alberta Health Services, Calgary, Alberta, T2N 4N2, Canada|The Ottawa Hospital Cancer Center, Ottawa, Ontario, K1H 8L6, Canada|Centre integre universitaire de sante et de services sociaux du Saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, G7H 5H6, Canada|CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, H2X 3E4, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Centre integre universitaire de sante et de services sociaux de l'Estrie, Sherbrooke, Quebec, J1H 5N4, Canada|Sociedad Prosalud Montes y Orlandi Ltda. Fantasy name (Orlandi Oncologia), Santiago, Metropolitana, 7500713, Chile|Centro de Investigacion Clinica del Sur, Temuco, Region DE LA Araucania, 4781156, Chile|Centro de Investigaciones Clinicas Vina del Mar, Vina del Mar, Valparaiso, 2540488, Chile|Centro de Investigaciones Clinicas Vina del Mar, Vina del Mar, Valparaiso, 2540634, Chile|James Lind Centro de Investigación del Cáncer, Araucania, 4800827, Chile|The First affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China|Beijing Cancer Hospital, Beijing, Beijing, 100142, China|Peking University Third Hospital, Beijing, Beijing, 100191, China|The First Affiliated Hospital Of Fujian Medical University, Fuzhou, Fujian, 350005, China|First Affiliated Hospital of Xiamen University, Xiamen, Fujian, 361003, China|Union Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei, 430022, China|Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China|The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, 222500, China|Nanjing First Hospital, Nanjing, Jiangsu, 210006, China|Nanjing Drum Tower Hospital , The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, 210008, China|Nanjing First Hospital, Nanjing, Jiangsu, 210012, China|Nantong Tumor Hospital, Nantong, Jiangsu, 226000, China|Second Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China|Wuxi People's Hospital, Wuxi, Jiangsu, 214023, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, China|Jilin Cancer Hospital, Changchun, Jilin, 130000, China|Zhongshan Hospital Fudan University, Shanghai, Shanghai, 200032, China|Shanghai General Hospital, Shanghai, Shanghai, 200080, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, 710061, China|West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, China|Yunnan Cancer Hospital, Kunming, Yunnan, 650118, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, 310014, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China|The first affiliated hospital of Ningbo university, Ningbo, Zhejiang, 315010, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China|Beijing Hospital, Beijing, 100010, China|Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China|Peking University First Hospital / Urology Department, Beijing, 100034, China|Chongqing University Cancer Hospital, Chongqing, 400030, China|Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China|Fudan University Cancer Hospital, Deptartment of Urology, Shanghai, 200032, China|Shanghai Tenth People's Hospital, Shanghai, 200072, China|The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, 201100, China|The Second Hospital of Tianjin Medical University, Tianjin, 300211, China|Fakultní nemocnice Hradec Králové, Hradec Kralove, 500 05, Czechia|Fakultni nemocnice Ostrava, Ostrava-Poruba, 708 52, Czechia|Multiscan s.r.o., Pardubice, 532 03, Czechia|Fakultní nemocnice Královské Vinohrady, Praha 10, 100 34, Czechia|HUS Helsinki University Hospital, Helsinki, 00029, Finland|Docrates Cancer Center, Helsinki, 00180, Finland|Kuopio University Hospital, Kuopio, 70210, Finland|Oulun yliopistollinen sairaala, Oulu, 90220, Finland|Tampere University Hospital, Tampere, 33520, Finland|Turku University Hospital, Turku, 20520, Finland|Clinique Victor Hugo Le Mans, Le Mans, Pays-de-la-loire, 72000, France|Centre d'Oncologie du Pays-Basque, Bayonne, 64100, France|Clinique Ramsay Belharra, Bayonne, 64100, France|Hopital Saint Andre - CHU de Bordeaux, Bordeaux, 33075, France|CHD Vendée, LA ROCHE SUR YON cedex 9, 85925, France|Centre Léon Bérard, Lyon CEDEX 08, 69373, France|CHU Montpellier-Hopital Saint Eloi, Montpellier cedex 5, 34295, France|Hopital Europeen Georges Pompidou, Paris Cedex 15, 75908, France|Hopital Saint-Louis, Paris, 75010, France|Clinique Sainte Anne, Strasbourg, 67000, France|Hopitaux Universitaires de Strasbourg - ICANS, Strasbourg, 67200, France|Hopital Foch, Suresnes Cedex, 92151, France|Hopital Foch, Suresnes, 92150, France|Institut Gustave Roussy, VILLEJUIF cedex, 94805, France|Universitaetsklinikum Duesseldorf, Duesseldorf, 40225, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany|Universitaetsklinik Heidelberg, Heidelberg, 69120, Germany|Diagnostikzentrum, Kirchheim, 73230, Germany|Universitaetsklinikum Muenster, Muenster, 48149, Germany|Studienpraxis Urologie, Nuertingen, 72622, Germany|Semmelweis Egyetem Urologiai Klinika, Budapest, 1082, Hungary|Országos Onkológiai Intézet, Budapest, 1122, Hungary|Uzsoki Utcai Korhaz, Budapest, 1145, Hungary|Uzsoki Utcai Kórház, Budapest, 1145, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, 4032, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont Onkoterapias Intezet, Pecs, 7624, Hungary|Rambam Health Care Campus, Haifa, 3109601, Israel|Shaare Zedek Medical Center, Jerusalem, 9103102, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, 6423906, Israel|Azienda Ospedaliero-Universitaria Policlinico Sant' Orsola Malpighi, Bologna, BO, 40138, Italy|ASST di Cremona, Cremona, CR, 26100, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, 47014, Italy|Azienda Ospedaliera S. Maria, Terni, TN, 05100, Italy|Ospedale Santa Chiara, Trento, TN, 38122, Italy|AOU San Luigi Gonzaga, Orbassano, TO, 10043, Italy|Istituto Nazionale Tumori IRCCS Fondazione G. Pascale - Napoli, Napoli, 80131, Italy|Nagoya University Hospital, Nagoya, Aichi, 466-8560, Japan|Hirosaki University School of Medicine & Hospital, Hirosaki, Aomori, 036-8563, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, 791-0280, Japan|National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima, 737-0023, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, 003-0804, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, 060-8648, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, 920-8641, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, 232-0024, Japan|Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, 238-8558, Japan|Osaka International Cancer Institute, Osaka-shi, Osaka, 5418567, Japan|Kindai University Hospital, Osakasayama, Osaka, 589-8511, Japan|Osaka University Hospital, Suita, Osaka, 565-0871, Japan|Hamamatsu University School of Medicine, University Hospital, Hamamatsu, Shizuoka, 431-3192, Japan|National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, 152-8902, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, 160-8582, Japan|Chiba Cancer Center, Chiba, 260-8717, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, 811-1395, Japan|Kagoshima University Hospital, Kagoshima, 890-8520, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto, 860-0008, Japan|Tokushima University Hospital, Tokushima, 770-8503, Japan|Yamagata Prefectural Central Hospital, Yamagata, 990-2292, Japan|Yamagata University Hospital, Yamagata, 990-9585, Japan|Clinical Trial Pharmacy, National Cancer Center, Goyang-si, Gyeonggi-do, 10408, Korea, Republic of|National Cancer Center, Goyang-si, Gyeonggi-do, 10408, Korea, Republic of|Pusan National University Hospital, Busan, 49241, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, 41404, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Cancer Center Clinical Trial, Asan Medical Center, Seoul, 05505, Korea, Republic of|Clinical Trials Center Pharmacy, Seoul, 06351, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Clinical Trial Pharmacy, The Catholic University of Korea, Seoul, 06591, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, 06591, Korea, Republic of|Tauranga Urology Research Limited, Tauranga, BAY OF Plenty, 3112, New Zealand|Canterbury District Health Board, Christchurch, Canterbury, 8011, New Zealand|Waikato Hospital, Hamilton, Waikato, 3204, New Zealand|Auckland City Hospital, Auckland, 1023, New Zealand|Sykehusapoteket Ostfold, Kalnes, Gralum, 1712, Norway|Ostfold County Hospital, Kalnes, Gralum, 1714, Norway|Akershus University Hospital, Lorenskog, 1478, Norway|Oslo University Hospital -Ullevål & Radiumhospitalet, Oslo, 0379, Norway|St. Olavs Hospital, Trondheim University Hospital, Trondheim, 7030, Norway|Clinica Monte Carmelo S.C.R.LTDA., Arequipa, Peru|Hospital Militar Central ""Coronel Luis Arias Schreiber"", Lima, Lima 11, Peru|Clinica Internacional Sede San Borja, Lima, Lima 41, Peru|Clinica Oncosalud, Lima, Lima 41, Peru|Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. ks. B. Markiewicza, Brzozow, 36-200, Poland|Szpitale Pomorskie Sp. z o.o. Oddzial Onkologii i Radioterapii, Gdynia, 81-519, Poland|Przychodnia Lekarska ""Komed"" Roman Karaszewski, Konin, 62-500, Poland|Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Otwock, 05-400, Poland|City Clinic Sp. z o.o., Warszawa, 02-473, Poland|NZOZ Szpital Mazovia; Oddzial urologiczny, Warszawa, 02-797, Poland|Centro Clínico Académico - Braga, Associação (2CABraga), Braga, 4710-243, Portugal|Instituto Português Oncologia de Coimbra Francisco Gentil - E.P.E, Coimbra, 3000-075, Portugal|Fundação Champalimaud, Lisboa, 1400-038, Portugal|Hospital da Luz Lisboa, Lisboa, 1500-650, Portugal|Centro Hospitalar do Porto - Hospital de Santo Antonio, Porto, 4099-001, Portugal|Instituto Português de Oncologia do Porto Francisco Gentil, Porto, 4200-072, Portugal|Cancercare Langenhoven Drive Oncology Centre, Port Elizabeth, Eastern CAPE, 6045, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, 2196, South Africa|Wits Clinical Research, Parktown, Gauteng, 2193, South Africa|Cancercare Rondebosch Oncology, Cape Town, Western CAPE, 7700, South Africa|Outeniqua Cancercare Oncology Unit, George, Western CAPE, 6530, South Africa|Cape Town Oncology Trials, Kraaifontein, Western CAPE, 7570, South Africa|Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruna, 15706, Spain|Hospital General Universitario de Elche, Elche, Alicante, 03203, Spain|Institut Catala d'Oncologia - ICO L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, 08908, Spain|Corporacio Sanitaria i Universitaria Parc Tauli, Sabadell, Barcelona, 08208, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, 30120, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|Hospital Universitario La Princesa, Madrid, 28006, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28009, Spain|MD Anderson Cancer Center, Madrid, 28033, Spain|Hospital Universitario 12 De Octubre, Madrid, 28041, Spain|Klinisk Provningsenhet (KPE) Onkologi, Goteborg, 413 45, Sweden|Patientomrade Backencancer, Tema Cancer, Stockholm, 171 76, Sweden|Cancercentrum, Umeå, 901 85, Sweden|University Hospitals Plymouth NHS Trust, Plymouth, Devon, PL6 8DH, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, OX3 9DU, United Kingdom|Greater Glasgow Health Board J B Russell House, Gartnavel Royal Hospital, Glasgow, Scotland, G12 0XH, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, CH63 4JY, United Kingdom|Royal Cornwall Hospitals NHS Trust, Cornwall, TR1 3LJ, United Kingdom|The Clatterbridge Cancer Centre - Liverpool, Liverpool, L7 8YA, United Kingdom|Imperial College Healthcare NHS Trust, London, W12 0HS, United Kingdom|Imperial College Healthcare NHS Trust, London, W2 1NY, United Kingdom|Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, W6 8RF, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/97/NCT03395197/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/97/NCT03395197/SAP_001.pdf"
